Artelo BiosciencesARTL -1.75%31 PB Ratio is 0.15 as of Jun. 26, 2026. GuruFocus rates ARTL with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,232 Biotechnology companies, Artelo Biosciences ranks better than 99.19% on this metric.
The historical rank and industry rank for Artelo Biosciences's PB Ratio or its related term are showing as below:
ARTL'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.15
Current: 0.15
During the past 12 years, Artelo Biosciences's highest PB Ratio was 0.15. The lowest was 0.00. And the median was 0.00.
ARTL's PB Ratio is ranked better than 99.19% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs ARTL: 0.15
During the past 12 months, Artelo Biosciences's average Book Value Per Share Growth Rate was -112.50% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Artelo Biosciences was 207.50% per year. The lowest was -51.50% per year. And the median was -32.40% per year.
Back to Basics: PB Ratio
Artelo Biosciences (NAS:ARTL) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Artelo Biosciences PB Ratio Related Terms
Artelo Biosciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Artelo Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Artelo Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artelo Biosciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artelo Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Artelo Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Artelo Biosciences (ARTL) has a PB Ratio of 0.15 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Artelo Biosciences and its competitors. According to the industry distribution chart, Artelo Biosciences ranks #10 out of 1232 companies in the Biotechnology industry, placing it in the top 0.8%.
Is Artelo Biosciences' PB Ratio too high?
Artelo Biosciences' current PB Ratio is 0.15. The Biotechnology industry median PB Ratio is 2.80. Artelo Biosciences' value of 0.15 is 94.6% below this industry median. Based on the distribution chart, Artelo Biosciences ranks #10 out of 1232 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Artelo Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' PB Ratio compare to RNAZ and GLMD?
According to the Biotechnology industry distribution chart, Artelo Biosciences ranks #10 out of 1232 companies for PB Ratio. This places Artelo Biosciences in the top 1% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. Artelo Biosciences' value of 0.15 is 94.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artelo Biosciences's current PB Ratio of 0.15 is 94.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Artelo Biosciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artelo Biosciences's current PB Ratio is 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTL) has a current PB Ratio of 0.15. The current PB Ratio is 0.15 and 94.6% below the Biotechnology industry median of 2.80. Artelo Biosciences' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Artelo Biosciences (ARTL), the current PB Ratio is 0.15 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
31GF Score
Get the complete analysis for ARTL
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARTL has been successfully added to your 
